Cormorant Asset Management’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,050,000
| Closed | -$41.7M | – | 52 |
|
|
2026
Q1 | $41.7M | Sell |
1,050,000
-275,000
| -21% | -$7.03M | 2.09% | 15 |
|
|
2025
Q4 | $33.1M | Sell |
1,325,000
-600,000
| -31% | -$15.2M | 1.53% | 19 |
|
|
2025
Q3 | $46.7M | Sell |
1,925,000
-161,600
| -8% | -$2.87M | 3.22% | 12 |
|
|
2025
Q2 | $27.4M | Sell |
2,086,600
-175,000
| -8% | -$2.22M | 2.04% | 15 |
|
|
2025
Q1 | $32.5M | Sell |
2,261,600
-300,000
| -12% | -$4.91M | 2.45% | 12 |
|
|
2024
Q4 | $42.9M | Hold |
2,561,600
| – | – | 2.36% | 12 |
|
|
2024
Q3 | $41M | Buy |
2,561,600
+950,000
| +59% | +$11.6M | 2.17% | 15 |
|
|
2024
Q2 | $14.6M | Buy |
1,611,600
+1,050,000
| +187% | +$9.96M | 0.84% | 32 |
|
|
2024
Q1 | $6.35M | Hold |
561,600
| – | – | 0.28% | 50 |
|
|
2023
Q4 | $4.47M | Hold |
561,600
| – | – | 0.21% | 43 |
|
|
2023
Q3 | $3.63M | Hold |
561,600
| – | – | 0.21% | 41 |
|
|
2023
Q2 | $3.48M | Hold |
561,600
| – | – | 0.19% | 54 |
|
|
2023
Q1 | $2.16M | Hold |
561,600
| – | – | 0.14% | 59 |
|
|
2022
Q4 | $1.74M | Sell |
561,600
-1,411,128
| -72% | -$5.23M | 0.12% | 61 |
|
|
2022
Q3 | $7.93M | Sell |
1,972,728
-954,545
| -33% | -$4.37M | 0.55% | 44 |
|
|
2022
Q2 | $14.3M | Buy |
2,927,273
+437,379
| +18% | +$2.8M | 1.08% | 32 |
|
|
2022
Q1 | $22.3M | Hold |
2,489,894
| – | – | 1.71% | 17 |
|
|
2021
Q4 | $28M | Buy |
2,489,894
+762,621
| +44% | +$10.3M | 1.67% | 20 |
|
|
2021
Q3 | $28.7M | Buy |
1,727,273
+300,000
| +21% | +$6.21M | 1.17% | 27 |
|
|
2021
Q2 | $31.1M | Buy |
+1,427,273
| New | +$33.5M | 1.05% | 28 |
|
Cormorant Asset Management's CNTA Position: Q2 2026 in Review
Cormorant Asset Management sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 1,050,000 shares — an estimated $41.7M sold.
Cormorant Asset Management first reported a position in CNTA in Q2 2021 and held it in 20 quarters. The position peaked at $46.7M in Q3 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Cormorant Asset Management reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Cormorant Asset Management sold 1,050,000 Centessa Pharmaceuticals shares in Q2 2026, an estimated $41.7M.
- Cormorant Asset Management first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 20 quarters.
- Cormorant Asset Management's Centessa Pharmaceuticals position peaked at $46.7M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.